Correlation between plasma long non-coding RNA MEG-3 and inflammatory cytokines in patients with diabetic nephropathy

Guo, Xingrong; Gan, Meishe; Zhou, Lian-Ji; Wei, Quan; Luo, Zuojie; Wang, Hua

doi:10.5414/cn110996

Cited by 2 publications

(3 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…133 However, plasma MEG3 and H19 levels are also potentially diagnostic and predictive in T2DM and its microvascular complications. 134,135 Abnormally elevated KCNQ1OT1 expression in PBMCs of patients with T2DM and DKD compared to non-diabetic controls may be a potential diagnostic and therapeutic biomarker for DKD. 131 Urine is also an ideal source of biomarkers for renal diseases.…”

Section: Lncrnas Applied In Dkd Diagnosismentioning

confidence: 99%

“…Serum NR_033515 levels were strongly associated with different stages of DKD and diagnostic markers of DKD (kidney injury molecule 1 and neutrophil gelatinase associated lipocalin) 133 . However, plasma MEG3 and H19 levels are also potentially diagnostic and predictive in T2DM and its microvascular complications 134,135 . Abnormally elevated KCNQ1OT1 expression in PBMCs of patients with T2DM and DKD compared to non‐diabetic controls may be a potential diagnostic and therapeutic biomarker for DKD 131 .…”

Section: Dkd‐related Lncrnas In Clinical Applicationmentioning

confidence: 99%

See 1 more Smart Citation

The role of long non‐coding RNAs in the development of diabetic kidney disease and the involved clinical application

Hou,

2024

Diabetes Metabolism Res

View full text Add to dashboard Cite

Diabetic kidney disease (DKD), one of the common microvascular complications of diabetes, is increasing in prevalence worldwide and can lead to End‐stage renal disease. However, there are still gaps in our understanding of the pathophysiology of DKD, and both current clinical diagnostic methods and treatment strategies have drawbacks. According to recent research, long non‐coding RNAs (lncRNAs) are intimately linked to the developmental process of DKD and could be viable targets for clinical diagnostic decisions and therapeutic interventions. Here, we review recent insights gained into lncRNAs in pathological changes of DKD such as mesangial expansion, podocyte injury, renal tubular injury, and interstitial fibrosis. We also discuss the clinical applications of DKD‐associated lncRNAs as diagnostic biomarkers and therapeutic targets, as well as their limitations and challenges, to provide new methods for the prevention, diagnosis, and treatment of DKD.

show abstract

Section: Lncrnas Applied In Dkd Diagnosismentioning

confidence: 99%

Section: Dkd‐related Lncrnas In Clinical Applicationmentioning

confidence: 99%

The role of long non‐coding RNAs in the development of diabetic kidney disease and the involved clinical application

Hou,

2024

Diabetes Metabolism Res

View full text Add to dashboard Cite

show abstract

“…Elevated inflammatory markers, including tumor necrosis factor-alpha (TNF-α), interleukin-1 beta (IL-1β), interleukin-6 (IL-6), and NOD-like receptor protein 3 (NLRP3), have been observed in the serum of DN rats ( Fu et al, 2017 ; Ou et al, 2021 ). Moreover, patients with type 2 diabetes nephropathy exhibit increased levels of interleukin-18 (IL-18) and IL-1β ( Buraczynska et al, 2019 ; Guo et al, 2023 ). Importantly, Duan et al identified inflammation as an independent risk factor for DN progression through renal biopsies ( Duan et al, 2021 ).…”

Section: Roles Of Alpinia Oxyphylla On Dnmentioning

confidence: 99%

Research progress on Alpinia oxyphylla in the treatment of diabetic nephropathy

Wang,

et al. 2024

Front. Pharmacol.

View full text Add to dashboard Cite

Diabetic nephropathy (DN) constitutes a major microvascular complication of diabetes and is a primary cause of mortality in diabetic individuals. With the global rise in diabetes, DN has become an urgent health issue. Currently, there is no definitive cure for DN. Alpinia oxyphylla, a Chinese herbal medicine traditionally used, exhibits a wide range of pharmacological effects and is frequently used in the prevention and management of DN. This paper offers an extensive review of the biological mechanisms by which A. oxyphylla delivers therapeutic advantages in DN management. These mechanisms include activating podocyte autophagy, regulating non-coding RNA, modulating gut microbiota, alleviating lipotoxicity, counteracting oxidative stress, and diminishing inflammatory responses, underscoring the therapeutic potential of A. oxyphylla in DN treatment.

show abstract

Correlation between plasma long non-coding RNA MEG-3 and inflammatory cytokines in patients with diabetic nephropathy

Cited by 2 publications

References 0 publications

The role of long non‐coding RNAs in the development of diabetic kidney disease and the involved clinical application

The role of long non‐coding RNAs in the development of diabetic kidney disease and the involved clinical application

Research progress on Alpinia oxyphylla in the treatment of diabetic nephropathy

Contact Info

Product

Resources

About